Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
0.7242
-0.0874 (-10.77%)
At close: Oct 7, 2026, 4:00 PM EDT
0.684257
-0.0399 (-5.52%)
After-hours: Oct 7, 2026, 6:00 PM EDT
Actuate Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Oral elraglusib is advancing to clinical trials, aiming to improve outcomes in metastatic pancreatic and other cancers by enhancing patient exposure and enabling synergistic combinations with RAS inhibitors. The program includes a robust pediatric strategy and is supported by strong clinical, preclinical, and regulatory progress.
Fiscal Year 2025
-
A large phase II randomized trial of elraglusib in first-line metastatic pancreatic cancer showed a significant and durable overall survival benefit, with a favorable safety profile and improved quality of life. The drug's unique mechanism and combinability position it as a promising new platform for pancreatic and other GI cancers.